Mark Youngblood

13PUBLICATIONS
90CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markersMolecular targetsGenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 12, 2026
DNA-PKcs inhibition sensitizes glioblastoma to radiotherapy through reprogramming of tumor cell states and immune microenvironment cell types.

|Feb 12, 2026
STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.

Mark W Youngblood, Shashwat Tripathi, Hinda Najem

|Dec 16, 2025
Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.

Mark W Youngblood, Abha Kumari, Yoon-Tae Kang

|Nov 26, 2025
Subgroup of meningiomas involving FOS and FOSB gene fusions.

Kanat Yalcin, Hasan Alanya, Batur Gultekin

|Mar 12, 2025
Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples.

Qixuan Wang, Juan Wang, Radhika Mathur

|May 11, 2024
The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.

S Joy Trybula, Mark W Youngblood, Constantine L Karras

Pageof 3

Frequent Collaborators

4 joint publications

Hinda Najem

4 joint publications

Amy Heimberger

4 joint publications

Craig M Horbinski

4 joint publications

David Raleigh